Baseline Gut Microbiota Composition Links Immune–nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study
Anticancer Research · 2026
DOI: 10.21873/anticanres.18400 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Anticancer Research, 2026. Verfasst von Fumihiro Shoji und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan; fumshoji@belle.shiga-med.ac.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Microbiome, Immune Checkpoint Inhibitors.
Themen: Mangelernährung
Abstract (Originalsprache)
BACKGROUND/AIM: Immune-nutritional status and gut microbiota composition have been proposed as biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC). However, their interrelationship and longitudinal dynamics during immunotherapy remain unclear. PATIENTS AND METHODS: In this multicenter prospective study, patients with advanced or recurrent NSCLC treated with atezolizumab-based immunotherapy were enrolled. Serial fecal samples were analyzed using 16S rRNA gene sequencing. Immune-nutritional status was evaluated using the prognostic nutritional index (PNI). Associations between baseline PNI, gut microbiota composition, treatment response, immune-related adverse events (irAEs), and longitudinal microbiota changes were assessed. RESULTS: Sixty-five patients were included (27 responders and 38 non-responders). Pretreatment PNI was significantly associated with treatment response (p=0.0048) and improved progression-free and overall survival. During follow-up, 12 patients (18.5%) developed irAEs. Lachnospiraceae UCG-008 was enriched in patients with high PNI and in those without irAEs. Longitudinal analysis showed stable abundance of this taxon during treatment with no significant temporal changes. CONCLUSION: Pretreatment gut microbiota composition was associated with immune-nutritional status and clinical outcomes in patients with NSCLC receiving atezolizumab-based immunotherapy. Lachnospiraceae UCG-008 was linked to favorable host status and lower irAE risk, remaining stable during treatment. These findings suggest that baseline gut microbiota may serve as a clinically relevant biomarker for both the efficacy and safety of immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan; fumshoji@belle.shiga-med.ac.jp.
- Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
- Department of Thoracic Surgery, Shiga University of Medical Science, Shiga, Japan.
- Department of Thoracic Surgery, Clinical Research Institute, NHO Kyushu Medical Center, Fukuoka, Japan.
- Department of Thoracic Surgery, Kitakyushu Medical Center, Kitakyushu, Japan.
- Department of Research and Development, Kyushu Pro Search LLP, Fukuoka, Japan.
Zitieren
APA
Shoji, F., Wakasu, S., Kosai, K., Kinoshita, F., Matsubara, T., Takamori, S., Kozuma, Y., Fujishita, T., Toyokawa, G., Tagawa, T., Tanaka, Y., Yamaguchi, M., Okamoto, T., Yamazaki, K., & Maehara, Y. (2026). Baseline Gut Microbiota Composition Links Immune–nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study. Anticancer Research. https://doi.org/10.21873/anticanres.18400
Vancouver
Shoji F, Wakasu S, Kosai K, Kinoshita F, Matsubara T, Takamori S, et al. Baseline Gut Microbiota Composition Links Immune–nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study. Anticancer Research. 2026. doi:10.21873/anticanres.18400
BibTeX
@article{Shoji2026,
author = {Shoji, Fumihiro and Wakasu, Sho and Kosai, Keisuke and Kinoshita, Fumihiko and Matsubara, Taichi and Takamori, Shinkichi and Kozuma, Yuka and Fujishita, Takatoshi and Toyokawa, Gouji and Tagawa, Tetsuzo and Tanaka, Yoshihide and Yamaguchi, Masafumi and Okamoto, Tatsuro and Yamazaki, Koji and Maehara, Yoshihiko},
title = {Baseline Gut Microbiota Composition Links Immune–nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18400}
}
EUVIMED